I am a scientist at the Agency for Science, Technology, and Research (A*STAR), and currently work at the Institute Of Sustainability for Chemicals, Energy And Environment (ISCE2).
I completed my PhD in Chemistry at the University of Cambridge in 2025. Before that, I was a Pharmacy graduate from the National University of Singapore (NUS) (2019).
My first foray into research was in 2011 as a young scientist at the Institute of Materials Research and Engineering (IMRE). Since then, I have worked in the following Research Entities (REs):
- Experimental Drug Development Centre (EDDC) (2019 – 2020)
- Bioinformatics Institute (BII) (2017)
- Institute of Bioengineering and Nanotechnology (2015)
My graduate research revolved around developing hypervalent iodine reagents for protein functionalisation. Before that, my undergraduate research work consisted of two research projects that revolved around tuberculosis: 1) discovering antitubercular agents that utilise new mechanisms of action against Mycobacterium tuberculosis, and 2) finding ways to reduce side effects of the tuberculosis drug regimens in use.
Liver-Chip: Reproducing Human and Cross-Species Toxicities
Zhang-He Goh
A Bile Duct-on-a-Chip with Organ-Level Functions
Zhang-He Goh
Engineered Enzymes that Retain and Regenerate their Cofactors Enable Continuous-Flow Biocatalysis
Zhang-He Goh
Aqueous synthesis of a small-molecule lanthanide chelator amenable to copper-free click chemistry
Zhang-He Goh
Applications of Machine Learning in Decision Analysis for Dose Management for Dofetilide
AND
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
Zhang-He Goh
Tracking the popularity and outcomes of all bioRxiv preprints
Dey Lab et al.
Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection
AND
Antimalarial drug mefloquine kills both trophozoite and cyst stages of Entamoeba
Zhang-He Goh
Robust Antibacterial Activity of Tungsten Oxide (WO3-X) Nanodots
Zhang-He Goh
A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
Zhang-He Goh
Drug prescription pattern in European neonatal units
Zhang-He Goh
A direct selection strategy for isolating aptamers with pH-sensitive binding activity
Zhang-He Goh
Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity
Zhang-He Goh
2 years
Zhang-He Goh
Thank you for pointing this out! I have now edited the Figure accordingly.